News & Updates

Show Multimedia Only
Bimekizumab safe, effective in moderate-to-severe plaque psoriasis

Bimekizumab safe, effective in moderate-to-severe plaque psoriasis

18 Sep 2023 byStephen Padilla

The high clinical response levels achieved with bimekizumab over 48 weeks persist up to week 96 in patients with moderate-to-severe plaque psoriasis, results of the BE RADIANT phase IIIb trial have shown. In addition, those on secukinumab who switched to bimekizumab have achieved similar responses at 96 weeks.

18 Sep 2023
Abrocitinib effectively controls AD regardless of dosing regimen

Abrocitinib effectively controls AD regardless of dosing regimen

03 Aug 2023 byAudrey Abella

In patients with moderate-to-severe atopic dermatitis (AD), flexible dosing of abrocitinib, an oral, once-daily Janus kinase 1-selective inhibitor, appeared as beneficial as the continuous high-dose regimen. This was demonstrated in a post hoc analysis of two studies from the JADE* clinical development programme.

03 Aug 2023